- Home
- SWTX
as 03-25-2025 4:00pm EST
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | STAMFORD |
| Market Cap: | 3.0B | IPO Year: | 2019 |
| Target Price: | $72.40 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.21 - $62.00 | Next Earning Date: | 05-01-2025 |
| Revenue: | $191,589,000 | Revenue Growth: | 3417.33% |
| Revenue Growth (this year): | 85.98% | Revenue Growth (next year): | 69.16% |
Stock Insider Trading Activity of SpringWorks Therapeutics Inc. (SWTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Edris Badreddin | SWTX | Chief Operating Officer | Mar 3 '25 | Sell | $54.68 | 20,000 | $1,084,592.24 | 169,712 | |
| Islam Saqib | SWTX | Chief Executive Officer | Feb 27 '25 | Sell | $55.08 | 49,000 | $2,657,655.82 | 992,069 | |
| Ashar Bhavesh | SWTX | Chief Commercial Officer | Feb 20 '25 | Sell | $61.19 | 1,016 | $62,168.13 | 62,053 | |
| Islam Saqib | SWTX | Chief Executive Officer | Feb 20 '25 | Sell | $60.67 | 29,328 | $1,768,400.79 | 992,069 | |
| LYNCH DANIEL | SWTX | Director | Feb 20 '25 | Sell | $60.69 | 47,600 | $2,866,534.08 | 86,526 | |
| Islam Saqib | SWTX | Chief Executive Officer | Feb 14 '25 | Sell | $59.92 | 10,672 | $639,489.72 | 992,069 | |
| LYNCH DANIEL | SWTX | Director | Feb 14 '25 | Sell | $60.00 | 400 | $24,000.00 | 86,526 | |
| Pichl Daniel | SWTX | Chief People Officer | Feb 10 '25 | Sell | $54.81 | 29,750 | $1,617,329.10 | 57,762 | |
| Edris Badreddin | SWTX | Chief Operating Officer | Feb 10 '25 | Sell | $53.13 | 30,000 | $1,593,795.00 | 169,712 | |
| Islam Saqib | SWTX | Chief Executive Officer | Feb 10 '25 | Sell | $53.30 | 48,000 | $2,558,236.80 | 992,069 |
Latest SpringWorks Therapeutics Inc. News
SWTX Breaking Stock News: Dive into SWTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
13 days ago
High Growth Tech Stocks In The US Market March 2025
Simply Wall St.
21 days ago
Investors push SpringWorks Therapeutics (NASDAQ:SWTX) 4.9% lower this week, company's increasing losses might be to blame
Insider Monkey
25 days ago
Is SpringWorks Therapeutics, Inc. (SWTX) The Best Immunology Stock To Buy Now?
GuruFocus.com
a month ago
SpringWorks Therapeutics Inc (SWTX) Q4 2024 Earnings Report Preview: What To Expect
GlobeNewswire
a month ago
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
PR Newswire
a month ago
SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over
TipRanks
a month ago
Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon
TipRanks
a month ago
SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg
Compare SWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SWTX SpringWorks Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.